# EDGAR Filing Document

**Accession Number:** 0001668673
**File Stem:** 0001628280-23-005559
**Filing Date:** 2023-2
**Character Count:** 47552
**Document Hash:** a94b81c58ceadeb370e06d31afc33811
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-005559.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001628280-23-005559

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230228

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PetIQ, Inc.
- **CENTRAL INDEX KEY:** 0001668673
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38163
- **FILM NUMBER:** 23685397

**BUSINESS ADDRESS:**
- **STREET 1:** PETIQ LLC
- **STREET 2:** 230 E. RIVERSIDE DR.
- **CITY:** EAGLE
- **STATE:** ID
- **ZIP:** 83616
- **BUSINESS PHONE:** 208-939-8900

**MAIL ADDRESS:**
- **STREET 1:** PETIQ LLC
- **STREET 2:** 230 E. RIVERSIDE DR.
- **CITY:** EAGLE
- **STATE:** ID
- **ZIP:** 83616

?xml version="1.0" ? petq-20230228

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 28, 2023**

**PETIQ, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br>(State or other jurisdiction<br>of incorporation) | **001-38163**<br>(Commission<br>File Number) | **35-2554312**<br>(I.R.S. Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **230 E. Riverside Dr.**<br>**Eagle, Idaho**<br>(Address of principal executive offices) | **83616**<br>(Zip Code) |

---

**(208) 939-8900**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>Title of Each Class</u> | <u>Trading Symbol</u> | <u>Name of Exchange on Which Registered</u> |
| Class A common stock, par value $0.001 per share | PETQ | The Nasdaq Global Select Market |

---

☐ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter)

☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

------

**Item 2.02 Results of Operations and Financial Condition.** 

On February 28, 2023, PetIQ, Inc. issued a press release announcing certain financial results for its three months and year ended December 31, 2022. A copy of the press release is attached hereto as Exhibit 99.1.

*The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.*

**Item 9.01. Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits

---

| | |
|:---|:---|
| <u>Exhibit Number</u> | <u>Description</u> |
| 99.1 | <u>[Press Release dated](petq-20230228xex991earning.htm)[February](petq-20230228xex991earning.htm)[28](petq-20230228xex991earning.htm)[, 202](petq-20230228xex991earning.htm)[3](petq-20230228xex991earning.htm)[announcing results for the three](petq-20230228xex991earning.htm)[months](petq-20230228xex991earning.htm)[and](petq-20230228xex991earning.htm)[year](petq-20230228xex991earning.htm)[ended](petq-20230228xex991earning.htm)[December 31](petq-20230228xex991earning.htm)[, 2022](petq-20230228xex991earning.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PETIQ, INC. | PETIQ, INC. |
| Dated: February 28, 2023 | By | /s/ Zvi Glasman |
|  | Name: | Zvi Glasman |
|  | Title: | Chief Financial Officer  |

---

## Exhibit 99.1

![petq-20220504xex99d1001.jpg](petq-20220504xex99d1001.jpg)

**PetIQ, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results**

*Full Year 2022 Net Sales and Adjusted EBITDA In-Line with Company Guidance*

*Updates Adjusted EBITDA Methodology*

*Reports Record Annual Cash from Operations of $48.0 Million*

*Completes Complementary, Margin Accretive Acquisition of Rocco & Roxie* 

*Provides First Quarter 2023 and Full Year 2023 Outlook*

EAGLE, Idaho – February 28, 2023 (GLOBE NEWSWIRE) - PetIQ, Inc. ("PetIQ" or the "Company") (Nasdaq: PETQ), a leading pet medication and wellness company, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Cord Christensen, PetIQ's Chairman & CEO commented, "We are pleased to report net sales and adjusted EBITDA in-line with our 2022 full year guidance as well as record annual cash generation. PetIQ captured a disproportionate amount of market share and outperformed the broader pet product categories in which we compete. Subsequent to year-end, we completed the complementary, strategic acquisition of Rocco & Roxie, helping us to enter new pet product categories. We expect to significantly increase Rocco & Roxie's points of distribution and expand pet product offerings over the next few years. Looking forward, we believe we are well positioned for solid growth in 2023 across our Product and Services segments to attract more pet parents to our health and wellness offerings."

**Full Year 2022 Highlights Compared to Prior Year** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales of $921.5 million, in-line with the Company's guidance of $920 million to $940 million, consisting of Product segment net sales of $800.3 million and Services segment net revenues of $121.2 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales for PetIQ's manufactured products increased to 29.3% of Product segment net sales compared to 27.7%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross margin increased 280 basis points to 22.8%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of $48.2 million, or a loss per share of $1.65, including a $47.3 million non-cash goodwill impairment charge recorded in the third quarter of 2022, compared to a net loss of $16.0 million, or a loss per share of $0.57

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net income of $17.7 million, or adjusted EPS of $0.61, an increase of 103.3% compared to adjusted net income of $8.3 million, or adjusted EPS of $0.30

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• EBITDA of $59.8 million, compared to EBITDA of $48.9 million, an increase of 22.4%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As previously disclosed in the Company's third quarter of 2022 earnings release, beginning in the fourth quarter of 2022, PetIQ changed its methodology of calculating Adjusted EBITDA to no longer add back non-same store sales, cost of sales and expenses and has recast prior year periods to conform to the new presentation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Based on this new methodology, Adjusted EBITDA was $77.7 million, compared to $69.7 million, an increase of 11.4%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Solely to allow investors to compare the Company's performance to the previously provided Adjusted EBITDA guidance, using its prior methodology, the Company would have reported Adjusted EBITDA of $94.1 million, compared to $92.9 million, an increase of 1.3% and in-line with the Company's previously provided guidance of $93.0 million to $95.0 million for 2022

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Aggregate net loss related to the Services segment wellness centers with less than six full quarters of operating results and pre-opening expenses, which we refer to as "non-same store operating results" of $16.4 million and $23.2 million for the full year ended December 31, 2022, and 2021, respectively

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Record cash from operations of $48.0 million and free cash flow of $36.1 million for the year ended December 31, 2022

------

**Fourth Quarter 2022 Highlights Compared to Prior Year Period**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales of $184.1 million, consisting of Product segment net sales of $157.3 million and Services segment net revenues of $26.8 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales for PetIQ's manufactured products remained relatively consistent at 30.7% of Product segment net sales compared to 30.8%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross margin increased 250 basis points to 21.3%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of $6.8 million, or a loss per share of $0.24, compared to a net loss of $14.0 million, or a loss per share of $0.49

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted net loss of $3.0 million, or adjusted loss per share of $0.10, compared to adjusted net loss of $6.5 million, or adjusted loss per share of $0.23

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• EBITDA of $9.9 million, compared to EBITDA of $4.8 million, an increase of 104.9%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Based on the Company's new methodology, Adjusted EBITDA was $12.9 million, compared to $9.1 million, an increase of 41.9%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-same store operating results of $2.8 million and $6.2 million for the fourth quarter of 2022 and 2021, respectively

------

**Fourth Quarter 2022 Financial Results**

Net sales were $184.1 million for the fourth quarter of 2022, a decrease of 6.4% compared to the prior year period, due to an 8.0% decrease in Product segment net sales compared to the prior year period. The decrease was primarily due to lapping the fill orders from a successful new product launch and stronger than normal sales at the end of the flea and tick season in the fourth quarter of 2021. The Company also continued to experience consumer trade down from premium to more value-oriented health and wellness products in the fourth quarter of 2022. Notably, the fourth quarter of the year is historically the seasonally lowest sales quarter for PetIQ based on the flea and tick season. This was partially offset by a 4.1% increase in Services segment net revenues as compared to the prior year period. Services segment net revenues benefited from improved revenue metrics and optimization of mobile clinics and wellness centers.

Fourth quarter 2022 gross profit was $39.3 million, an increase of 6.5%, compared to $36.9 million in the prior year period. Gross margin increased 250 basis points to 21.3% from 18.8% in the prior year period primarily as a result of favorable product mix and price.

Selling, general and administrative expenses ("SG&A") was $37.7 million for the fourth quarter of 2022 compared to $41.5 million in the prior year period. Adjusted SG&A was $34.7 million for the fourth quarter of 2022 compared to $37.2 million in the prior year period. As a percentage of net sales adjusted SG&A was 20.5%, a decrease of 60 basis points compared to the prior year period primarily as a result of expense efficiency initiatives.

Net loss was $6.8 million for the fourth quarter of 2022, compared to a net loss of $14.0 million in the prior year period. Adjusted net loss for the fourth quarter of 2022 was $3.0 million and adjusted loss per diluted share was $0.10, compared to adjusted net loss of $6.5 million, and adjusted loss per share of $0.23 in the prior year period.

EBITDA was $9.9 million for the fourth quarter of 2022 compared to $4.8 million in the prior year period, an increase of 104.9%. Beginning in the fourth quarter of 2022, PetIQ is no longer adding back non-same store operating results in the calculation of Adjusted EBITDA. Under this new methodology, fourth quarter adjusted EBITDA was $12.9 million, an increase of 41.9%, compared to $9.1 million in the prior year period. The new methodology for Adjusted EBITDA does not give effect to non-same store operating results of $2.8 million and $6.2 million for the fourth quarter of 2022 and 2021, respectively. Adjusted EBITDA margin increased 240 basis points to 7.0% compared to 4.6% in the prior year period.

Adjusted SG&A, adjusted net income (loss), adjusted earnings (loss) per share, adjusted EBITDA, adjusted EBITDA margin and free cash flow are non-GAAP financial measures. The Company believes these non-GAAP financial measures provide investors with additional insight into the way management views the business. See "Non-GAAP Financial Measures" for a definition of these measures and the financial tables that accompany this release for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measure.

**Cash Flow and Balance Sheet**

The Company ended the quarter with total cash and cash equivalents of $101.3 million. For the year ended December 31, 2022, the Company generated record cash from operations and free cash flow of $48.0 million and $36.1 million, respectively. The Company's total debt was $452.9 million as of December 31, 2022. The Company had total liquidity, which it defines as cash on hand plus debt availability, of $226.3 million as of December 31, 2022. The Company's net leverage as measured under the Company's credit agreement was 3.7x as of December 31, 2022. Please refer to the financial table within this press release for a calculation of the Company's net leverage under the credit agreement.

------

**Completes Acquisition of Rocco & Roxie**

On January 13, 2023, the Company completed the acquisition of all of the outstanding membership units of Rocco & Roxie LLC ("Rocco & Roxie"). This complementary, margin accretive acquisition expands PetIQ's brand and product portfolio to primarily include stain and odor products, jerky treats and behavior products. PetIQ expects to significantly expand Rocco & Roxie's points of distribution beyond e-commerce to brick-and-mortar retail, to increase growth of its existing pet product offerings and to introduce new SKUs. Rocco & Roxie generated approximately $29.0 million of net sales for the year ended December 31, 2022. As a result of the acquisition, Rocco & Roxie is now a wholly owned subsidiary of PetIQ.

**Outlook** 

For the full year 2023 the Company expects:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales of $970 million to $1,030 million, an increase of approximately 9.0% compared to 2022 based on the mid-point of the guidance

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $86 million to $92 million, an increase of approximately 15.0% compared to 2022 based on the mid-point of the guidance using the Company's new methodology

For the first quarter of 2023 the Company expects:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net sales of $270 million to $290 million, an increase of approximately 2.0% compared to the prior year period based on the mid-point of the guidance

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $27 million to $29 million, an increase of approximately 15.0% compared to the prior year period based on the mid-point of the guidance using the Company's new methodology

The Company does not provide guidance for net income (loss), the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between its forecasted adjusted EBITDA and net income (loss) without unreasonable effort due to the unavailability of reliable estimates for certain components of net income and the respective reconciliations. These forecasted items are not within the Company's control, may vary greatly between periods and could significantly impact future financial results for the first quarter ending March 31, 2023 and full year ending December 31, 2023.

**Conference Call and Webcast** 

The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin today at 4:30 p.m. ET. To participate on the live call listeners in North America may dial 844-826-3033 and international listeners may dial 412-317-5185.

In addition, the call will be broadcast live over the Internet hosted at the "Investors" section of the Company's website at www.PetIQ.com. A telephonic playback will be available through Tuesday, March 21, 2023. North American listeners may dial 844-512-2921 and international listeners may dial 412-317-6671; the passcode is 10175139.

**About PetIQ**

PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications, which is further supported by its own world-class medications manufacturing facility in Omaha, Nebraska. The company's national service platform, VIP Petcare, operates in over 2,600 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.

**Contact:** katie.turner@petiq.com or 208.513.1513

------

**Forward Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, such as statements about our plans, objectives, expectations, assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could" and similar expressions. Forward-looking statements involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results, performances, or achievements expressed or implied by the forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to: changes in general economic or market conditions, including inflation, that could affect overall consumer spending or our industry; the impact of COVID-19 on our business and the global economy; our ability to successfully grow our business through acquisitions and our ability to integrate acquisitions, including Rocco & Roxie; our dependence on a limited number of customers; our ability to implement our growth strategy effectively; competition from veterinarians and others in our industry; reputational damage to our brands; economic trends and spending on pets; the effectiveness of our marketing and trade promotion programs; recalls or withdrawals of our products or product liability claims; our ability to manage our manufacturing and supply chain effectively; disruptions in our manufacturing and distribution chains; our ability to introduce new products and improve existing products; our ability to protect our intellectual property; costs associated with governmental regulation; our ability to keep and retain key employees; our ability to achieve or sustain profitability; and the risks set forth under the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2022 and other reports filed time to time with the Securities and Exchange Commission. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results. The forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Consequently, you should not place undue reliance on forward-looking statements.

**Non-GAAP Financial Measures** 

In addition to financial results reported in accordance with U.S. GAAP, PetIQ uses the following non-GAAP financial measures: adjusted net income (loss), adjusted earnings (loss) per share, adjusted SG&A, adjusted EBITDA, adjusted EBITDA margin and free cash flow.

Adjusted net income (loss) consists of net income (loss) adjusted for tax expense, non-cash goodwill impairment charge, acquisition expenses, integration costs, loss on debt extinguishment and related costs, litigation costs, and stock-based compensation expense. Adjusted net income (loss) is utilized by management to evaluate the effectiveness of our business strategies. Non-GAAP adjusted earnings (loss) per share is defined as non-GAAP adjusted net income (loss) divided by the weighted average number of shares of common stock outstanding during the period.

Adjusted SG&A consists of SG&A adjusted for acquisition expenses, stock-based compensation expense, loss on debt extinguishment and related costs, integration costs, CFO Transition costs, and litigation expense.

EBITDA represents net income before interest, income taxes, depreciation and amortization and a non-cash goodwill impairment charge. Adjusted EBITDA represents EBITDA plus adjustments for transactions that management does not believe are representative of our core ongoing business including acquisition costs, loss

------

on extinguishment of debt, stock-based compensation expense, CFO Transition costs, integration costs and litigation expenses. Adjusted EBITDA margin is adjusted EBITDA stated as a percentage of net sales.

Adjusted EBITDA is utilized by management: as a factor in evaluating management's performance when determining incentive compensation and to evaluate the effectiveness of our business strategies. The Company presents EBITDA because it is a necessary component for computing adjusted EBITDA.

Free cash flow consists of cash provided by operations less capital expenditures.

We believe that the use of these non-GAAP measures provides additional tools for investors to use in evaluating ongoing operating results and trends. In addition, you should be aware when evaluating these non-GAAP measures that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by these or other unusual or non-recurring items. Our computation of non-GAAP measures may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate these non-GAAP measures in the same manner. Our management does not, and you should not, consider the non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in our financial statements. See a reconciliation of each non-GAAP measure to the most comparable GAAP measure, in the financial tables that accompany this release.

------

**PetIQ, Inc.**

**Consolidated Balance Sheets**

**(Unaudited, in 000's except for per share amounts)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2022** | **December 31, 2021** |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $101265 | $79406 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 118004 | 113947 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | 142605 | 96440 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 8238 | 8896 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 370112 | 298689 |
| &nbsp;&nbsp;&nbsp;Property, plant and equipment, net | 73395 | 76613 |
| &nbsp;&nbsp;&nbsp;Operating lease right of use assets | 18231 | 20489 |
| &nbsp;&nbsp;&nbsp;Other non-current assets | 1373 | 2024 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 172479 | 190662 |
| &nbsp;&nbsp;&nbsp;Goodwill | 183306 | 231110 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $818896 | $819587 |
| Liabilities and equity |  |  |
| &nbsp;&nbsp;&nbsp;Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $112995 | $55057 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued wages payable | 11512 | 12704 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest payable | 1912 | 3811 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued expenses | 7725 | 11680 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating leases | 6595 | 6500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt and finance leases | 8751 | 8350 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 149490 | 98102 |
| &nbsp;&nbsp;&nbsp;Operating leases, less current installments | 12405 | 14843 |
| &nbsp;&nbsp;&nbsp;Long-term debt, less current installments | 443276 | 448470 |
| &nbsp;&nbsp;&nbsp;Finance leases, less current installments | 907 | 2493 |
| &nbsp;&nbsp;&nbsp;Other non-current liabilities | 1025 | 459 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total non-current liabilities | 457613 | 466265 |
| Equity |  |  |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 378709 | 368006 |
| &nbsp;&nbsp;&nbsp;Class A common stock, par value $0.001 per share, 125,000 shares authorized; 29,348 and 29,139 shares issued, respectively | 29 | 29 |
| &nbsp;&nbsp;&nbsp;Class B common stock, par value $0.001 per share, 8,402 shares authorized; 252 and 272 shares issued and outstanding, respectively  |  |  |
| &nbsp;&nbsp;&nbsp;Class A treasury stock, at cost, 373 and 0 shares, respectively | (3857) |  |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (162733) | (114525) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (2224) | (684) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 209924 | 252826 |
| &nbsp;&nbsp;&nbsp;Non-controlling interest | 1869 | 2394 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 211793 | 255220 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $818896 | $819587 |

---

------

**PetIQ, Inc.**

**Consolidated Statements of Operations** 

 **(Unaudited, in 000's, except for per share amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three Months Ended** | **For the Three Months Ended** | **For the Twelve Months Ended** | **For the Twelve Months Ended** |
| | **December 31, 2022** | **December 31, 2021** | **December 31, 2022** | **December 31, 2021** |
| Product sales | $157324 | $170947 | $800305 | $825395 |
| Services revenue | 26755 | 25689 | 121208 | 107133 |
| Total net sales | 184079 | 196636 | 921513 | 932528 |
| Cost of products sold | 120715 | $135729 | 606548 | 646402 |
| Cost of services | 24080 | $24013 | 105302 | 99733 |
| Total cost of sales | 144795 | 159742 | 711850 | 746135 |
| Gross profit | 39284 | 36894 | 209663 | 186393 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 37747 | 41455 | 182561 | 170521 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment |  |  | 47264 |  |
| Operating income (loss) | 1537 | (4561) | (20162) | 15872 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 7678 | 6003 | 27374 | 24696 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on debt extinguishment |  |  |  | 5453 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense (income), net | (98) | 229 | (130) | (1763) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense, net | 7580 | 6232 | 27244 | 28386 |
| Pretax net loss | (6043) | (10793) | (47406) | (12514) |
| Income tax expense | (845) | (3682) | (1214) | (3869) |
| Net loss | (6888) | (14475) | (48620) | (16383) |
| Net loss attributable to non-controlling interest | (52) | (426) | (412) | (416) |
| Net loss attributable to PetIQ, Inc. | $(6836) | $(14049) | $(48208) | $(15967) |
| **Net loss per share attributable to PetIQ, Inc. Class A common stock** | **Net loss per share attributable to PetIQ, Inc. Class A common stock** | **Net loss per share attributable to PetIQ, Inc. Class A common stock** | **Net loss per share attributable to PetIQ, Inc. Class A common stock** |  |
| &nbsp;&nbsp;&nbsp;Basic | $(0.24) | $(0.49) | $(1.65) | $(0.57) |
| &nbsp;&nbsp;&nbsp;Diluted | $(0.24) | $(0.49) | $(1.65) | $(0.57) |
| **Weighted Average shares of Class A common stock outstanding** | **Weighted Average shares of Class A common stock outstanding** | **Weighted Average shares of Class A common stock outstanding** | **Weighted Average shares of Class A common stock outstanding** |  |
| &nbsp;&nbsp;&nbsp;Basic | 28967 | 28940 | 29159 | 28242 |
| &nbsp;&nbsp;&nbsp;Diluted | 28967 | 28940 | 29159 | 28242 |

---

------

**PetIQ, Inc.**

 **Consolidated Statements of Cash Flows**

**(Unaudited, in 000's)**

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2022** | **2021** |
| Cash flows from operating activities |  |  |
| &nbsp;&nbsp;Net loss | $(48620) | $(16383) |
| &nbsp;&nbsp;Adjustments to reconcile net loss to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation, amortization of intangible assets and loan fees | 35468 | 39300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | 47264 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on debt extinguishment |  | 5453 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on disposition of property, plant, and equipment | 438 | (1183) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation expense | 11363 | 9428 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax adjustment | 599 | 3487 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-cash activity | (385) | 233 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (4137) | (11197) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (46297) | 1283 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | 1093 | (1380) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 58546 | (12131) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued wages payable | (1225) | 2194 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued expenses | (6083) | 4663 |
| Net cash provided by operating activities | 48024 | 23767 |
| Cash flows from investing activities |  |  |
| &nbsp;&nbsp;Proceeds from disposition of property, plant, and equipment |  | 5132 |
| &nbsp;&nbsp;Purchase of property, plant, and equipment | (11973) | (31270) |
| Net cash used in investing activities | (11973) | (26138) |
| Cash flows from financing activities |  |  |
| &nbsp;&nbsp;Proceeds from issuance of long-term debt | 59000 | 642568 |
| &nbsp;&nbsp;Principal payments on long-term debt | (66600) | (597071) |
| &nbsp;&nbsp;Tax distributions to LLC Owners |  | (70) |
| &nbsp;&nbsp;Principal payments on finance lease obligations | (1493) | (1926) |
| &nbsp;&nbsp;Payment of deferred financing fees and debt discount |  | (7656) |
| &nbsp;&nbsp;Tax withholding payments on Restricted Stock Units | (875) | (937) |
| &nbsp;&nbsp;Stock repurchase | (3857) |  |
| &nbsp;&nbsp;Exercise of options to purchase class A common stock | 115 | 13426 |
| Net cash (used in) provided by financing activities | (13710) | 48334 |
| Net change in cash and cash equivalents | 22341 | 45963 |
| Effect of exchange rate changes on cash and cash equivalents | (482) | (13) |
| Cash and cash equivalents, beginning of period | 79406 | 33456 |
| Cash and cash equivalents, end of period | $101265 | $79406 |

---

------

**PetIQ, Inc.**

**Summary Segment Results**

(**Unaudited, in 000's)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three Months Ended** | **For the Three Months Ended** | **For the Twelve Months Ended** | **For the Twelve Months Ended** |
|<br>***$'s in 000's*** | **December 31, 2022** | **December 31, 2021** | **December 31, 2022** | **December 31, 2021** |
| Products segment sales | $157324 | $170947 | $800305 | $825395 |
| Services segment revenue: |  |  |  |  |
| &nbsp;&nbsp;Same-store sales | 23846 | 18133 | 102426 | 81955 |
| &nbsp;&nbsp;Non same-store sales | 2909 | 7556 | 18782 | 25178 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total services segment revenue | $26755 | $25689 | $121208 | $107133 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total net sales | $184079 | $196636 | $921513 | $932528 |

---

**PetIQ, Inc.**

**Reconciliation between Selling, General & Administrative ("SG&A") and Adjusted SG&A**

(**Unaudited, in 000's, Except for Percentages)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three Months Ended** | **For the Three Months Ended** | **For the Twelve Months Ended** | **For the Twelve Months Ended** |
|<br>***$'s in 000's*** | **December 31, 2022** | **December 31, 2021** | **December 31, 2022** | **December 31, 2021** |
| SG&A | $37747 | $41455 | $182561 | $170521 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;Acquisition costs<sup>(2)</sup> | 273 |  | 1464 | 92 |
| &nbsp;&nbsp;Loss on debt extinguishment and related costs<sup>(3)</sup> |  |  |  | 985 |
| &nbsp;&nbsp;Stock based compensation expense | 2459 | 2240 | 11363 | 9428 |
| &nbsp;&nbsp;CFO Transition |  | 597 |  | 928 |
| &nbsp;&nbsp;Integration costs<sup>(4)</sup> | 228 | 212 | 1171 | (142) |
| &nbsp;&nbsp;Litigation expenses | 60 | 1219 | 3862 | 4105 |
| Adjusted SG&A<sup>(5)</sup> | $34727 | $37187 | $164701 | $155125 |
| % of Total Net Sales (GAAP) | 20.5% | 21.1% | 19.8% | 18.3% |

---

------

**PetIQ, Inc.**

**Reconciliation between Net Loss and Adjusted EBITDA**

(**Unaudited, in 000's)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three Months Ended** | **For the Three Months Ended** | **For the Twelve Months Ended** | **For the Twelve Months Ended** |
|<br>***$'s in 000's*** | **December 31, 2022** | **December 31, 2021** | **December 31, 2022** | **December 31, 2021** |
| Net loss | (6888) | (14475) | (48620) | (16383) |
| Plus: |  |  |  |  |
| &nbsp;&nbsp;Tax expense | 845 | 3682 | 1214 | 3869 |
| &nbsp;&nbsp;Depreciation | 3747 | 4947 | 14520 | 14366 |
| &nbsp;&nbsp;Amortization | 4477 | 4654 | 18079 | 22336 |
| &nbsp;&nbsp;Goodwill impairment<sup>(1)</sup> |  |  | 47264 |  |
| &nbsp;&nbsp;Interest expense, net | 7678 | 6003 | 27374 | 24696 |
| EBITDA | 9860 | 4811 | 59831 | 48884 |
| &nbsp;&nbsp;Acquisition costs<sup>(2)</sup> | 273 |  | 1464 | 92 |
| &nbsp;&nbsp;Loss on debt extinguishment and related costs<sup>(3)</sup> |  |  |  | 6438 |
| &nbsp;&nbsp;Stock based compensation expense | 2459 | 2240 | 11363 | 9428 |
| &nbsp;&nbsp;Integration costs<sup>(4)</sup> | 228 | 212 | 1171 | (142) |
| &nbsp;&nbsp;Litigation expenses | 60 | 1219 | 3862 | 4105 |
| &nbsp;&nbsp;CFO Transition |  | 597 |  | 928 |
| Adjusted EBITDA<sup>(5)</sup> | 12879 | 9079 | 77691 | 69733 |
| *Adjusted EBITDA Margin* | 7.0% | 4.6% | 8.4% | 7.5% |

---

------

**PetIQ, Inc.**

**Reconciliation between Net Loss and Adjusted Net (Loss) Income**

(**Unaudited, in 000's, except for per share amounts)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Three Months Ended** | **For the Three Months Ended** | **For the Twelve Months Ended** | **For the Twelve Months Ended** |
|<br>***$'s in 000's*** | **December 31, 2022** | **December 31, 2021** | **December 31, 2022** | **December 31, 2021** |
| Net loss | $(6888) | $(14475) | $(48620) | $(16383) |
| Plus: |  |  |  |  |
| &nbsp;&nbsp;Tax expense | 845 | 3682 | 1214 | 3869 |
| &nbsp;&nbsp;Goodwill impairment<sup>(1)</sup> |  |  | 47264 |  |
| &nbsp;&nbsp;Acquisition costs<sup>(2)</sup> | 273 |  | 1464 | 92 |
| &nbsp;&nbsp;Loss on debt extinguishment and related costs<sup>(3)</sup> |  |  |  | 6438 |
| &nbsp;&nbsp;Stock based compensation expense | 2459 | 2240 | 11363 | 9428 |
| &nbsp;&nbsp;Integration costs<sup>(4)</sup> | 228 | 212 | 1171 | (142) |
| &nbsp;&nbsp;Litigation expenses | 60 | 1219 | 3862 | 4105 |
| &nbsp;&nbsp;CFO Transition |  | 597 |  | 928 |
| Adjusted Net (loss) income<sup>(5)</sup> | $(3023) | $(6525) | $17718 | $8335 |
| Non-GAAP adjusted EPS |  |  |  |  |
| Basic | $(0.10) | $(0.23) | $0.61 | $0.30 |
| Diluted | $(0.10) | $(0.23) | $0.61 | $0.30 |
| Weighted Average shares of Class A common stock outstanding used to compute non-GAAP adjusted EPS | Weighted Average shares of Class A common stock outstanding used to compute non-GAAP adjusted EPS | Weighted Average shares of Class A common stock outstanding used to compute non-GAAP adjusted EPS | Weighted Average shares of Class A common stock outstanding used to compute non-GAAP adjusted EPS | Weighted Average shares of Class A common stock outstanding used to compute non-GAAP adjusted EPS |
| Basic | 28967 | 28940 | 29159 | 28242 |
| Diluted | 28967 | 28940 | 29159 | 28242 |

---

<sup>(1)</sup> Non-cash goodwill impairment due to a significant decline in the Company's market capitalization, driven primarily by rising interest rates and macroeconomic conditions. Additionally, the Company made the strategic decision to slow expansion plans for the Services business this year.

<sup>(2)</sup> Acquisition costs include legal, accounting, banking, consulting, diligence, and other costs related to completed and contemplated acquisitions.

<sup>(3)</sup> Loss on debt extinguishment and related costs are related to our entering into two new credit facilities, including the write off of deferred financing costs and related costs.

<sup>(4)</sup> Integration costs represent costs related to integrating the acquired businesses including personnel costs such as severance and signing bonuses, consulting costs, contract termination, and IT conversion costs. The costs are primarily within the Products segment.

<sup>(5)</sup> Effective December 31, 2022, the Company no longer includes non same-store operating results related to the Services segment wellness centers with less than six full quarters of operating results, and pre-opening expenses, as an adjustment to its calculation of its non-GAAP financial measures. As a result, the following non-GAAP measures have been recast for comparability to remove non same-store operating results for the three months ended December 31, 2022 and 2021 and the twelve months ended December 31, 2022 and 2021 as follows:

• Adjusted SG&A- $0, $2.9, $5.7, and $8.0, million respectively

• Adjusted net income- $2.8, $6.2, $16.4, and $23.2, million respectively

• Adjusted EBITDA- $2.8, $6.2, $16.4, and $23.2, million respectively

------

**PetIQ, Inc.**

**Calculation of Net Leverage Ratio Under Term Loan B**

(**Unaudited, in 000's, except for multiples)** 

---

| | |
|:---|:---|
| | **December 31, 2022** |
| Total debt | $450409 |
| &nbsp;&nbsp;&nbsp;Total Capital Leases | 2525 |
| &nbsp;&nbsp;&nbsp;Less Cash | (101265) |
| Net Debt | 351669 |
| LTM Term Loan B defined EBITDA | 94114 |
| Term Loan B net leverage<sup>(1)</sup> | 3.7x |

---

<sup>(1)</sup> Our Term Loan B documentation defines Adjusted EBITDA as net income before interest, income taxes, depreciation and amortization and a non-cash goodwill impairment charge, as further adjusted for acquisition costs, loss on debt extinguishment and related costs, stock based compensation expense, integration costs, litigation expenses, CFO transition costs and non same-store net income (loss), which we refer to as "Term Loan B Adjusted EBITDA." Term Loan B Adjusted EBITDA is not a non-GAAP measure and is presented solely for purposes of providing investors an understanding of the Company's financial condition and liquidity and should not be relied upon for any purposes other than an understanding of the Company's financial condition and liquidity as it relates to the Company's Term Loan B.

**PetIQ, Inc.**

**Free Cash Flow**

(**Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Year ended December 31** | **Year ended December 31** |
|<br>***$'s in 000's*** | **2022** | **2021** |
| Net cash provided by (used in) operating activities | $48024 | $23767 |
| &nbsp;&nbsp;Less purchase of property, plant, and equipment | (11973) | (31270) |
| Free Cash Flow | 36051 | (7503) |

---

------

We utilize Segment Adjusted EBITDA as our segment performance measure. This segment performance measure is required to be disclosed by U.S. GAAP in accordance with FASB Accounting Standard Codification ("ASC") 280 - Segment Reporting. When presented by segment, we have prepared the reconciliation of Segment Adjusted EBITDA to the corresponding consolidated U.S. GAAP total in accordance with the disclosure requirements as articulated in ASC 280.

**PetIQ, Inc.**

**Reconciliation of Segment Adjusted EBITDA to Net Loss**

**(Unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| | **For the years ended** | **For the years ended** | **For the years ended** |
| ***$'s in 000's*** | **December 31, 2022** | **December 31, 2021** | **December 31, 2020** |
| **Segment Adjusted EBITDA:** | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Product<sup>(1)</sup> | $90333 | $88982 | $68084 |
| &nbsp;&nbsp;&nbsp;&nbsp;Services<sup>(1)</sup> | 3781 | 3910 | (292) |
| Total | 94114 | 92892 | 67792 |
| **Adjustments:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | (14520) | (14366) | (12082) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | (18079) | (22336) | (12815) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest | (27374) | (24696) | (22807) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on debt extinguishment and related costs<sup>(2)</sup> |  | (6438) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition costs<sup>(3)</sup> | (1464) | (92) | (2620) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation expense | (11363) | (9428) | (9170) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non same-store adjustment<sup>(4)</sup> | (16423) | (23159) | (16354) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Integration costs<sup>(5)</sup> | (1171) | 142 | (9776) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation expenses | (3862) | (4105) | (1006) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COVID-19 related costs<sup>(6)</sup> |  |  | (6476) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CFO Transition |  | (928) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment<sup>(7)</sup> | (47264) |  |  |
| **Pretax net loss** | $(47406) | $(12514) | $(25314) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | (1214) | (3869) | (60413) |
| **Net loss** | $(48620) | $(16383) | $(85727) |

---

<sup>(1)</sup> Beginning in the fourth quarter of 2022, the Company is allocating corporate expenses to each segment pro rata based on net sales for each segment. The presentation of Product Adjusted EBITDA and Segment Adjusted EBITDA for the years ended December 31, 2021 and 2020 have been recast for comparability. For the years ended December 31, 2022, 2021 and 2020, total corporate expenses were $75.5 (of which $65.6 million was allocated to Products and $9.9 million was allocated to Segments), $68.2 million (of which $60.4 million was allocated to Products and $7.8 million was allocated to Segments) and $52.8 million (of which $49.1 million was allocated to Products and $3.7 million was allocated to Segments), respectively.

<sup>(2)</sup> Loss on debt extinguishment and related costs are related to our entering into two new credit facilities, including the write off of deferred financing costs and related costs.

<sup>(3)</sup> Acquisition costs include legal, accounting, banking, consulting, diligence, and other costs related to completed and contemplated acquisitions.

<sup>(4)</sup> Non same-store revenue and costs relate to our Services segment and are from wellness centers with less than six full quarters of operating results. This includes clinic launch expenses.

<sup>(5)</sup> Integration costs represent costs related to integrating the acquired businesses including personnel costs such as severance and signing bonuses, consulting costs, contract termination, and IT conversion costs. The costs are primarily within the Products segment.

<sup>(6)</sup> Costs related to maintaining service segment infrastructure, staffing, and overhead related to clinics and wellness centers closed due to COVID-19 related health and safety initiatives. Product segment costs related to incremental wages paid to essential workers and sanitation costs due to COVID.

------

<sup>(7)</sup> Non-cash goodwill impairment due to a significant decline in the Company's market capitalization, driven primarily by rising interest rates and macroeconomic conditions. Additionally, the Company made the strategic decision to slow expansion plans for the Services business.

<br>